6578.TWO Dabomb Protein
- Market cap
- TWD 1.21B
- P/E
- -
- P/B
- 1.24x
- ROE
- 2.9%
- Dividend yield
- 1.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6578.TWO undervalued?
Graham numberThe Graham number of Dabomb Protein cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dabomb Protein fundamental analysis
No fundamental analysis for Dabomb Protein yet.
Dabomb Protein stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers nutrition and health care for aquatic products and economic animals; and pet health care products. The company also offers contract development and manufacturing organization services, including research and development, process design, and mass production services; product packaging solutions; and product formulation design and cus…
Full company profileDabomb Protein financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dabomb Protein annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 727M | 562M | 623M | 647M | 605M | 471M | 434M | 384M | 338M | 309M | 379M |
| Gross Profit | 167M | 121M | 117M | 130M | 99.3M | 21.7M | 19.3M | 46.4M | 68.7M | 69.0M | 92.0M |
| Operating Income | 83.5M | 41.1M | 31.2M | 39.1M | 14.2M | -67.0M | -42.5M | -47.7M | -1.82M | -28.2M | 21.6M |
| EBITDA | - | 52.0M | 46.9M | 49.9M | 39.8M | -40.8M | -15.5M | -26.0M | 35.0M | -22.2M | 63.6M |
| Net Income | 68.3M | 28.0M | 25.1M | 21.2M | 7.19M | -62.4M | -44.7M | -57.0M | 11.6M | -69.3M | 29.5M |
| EPS | - | 1.09 | 0.86 | 0.72 | 0.22 | -1.92 | -1.15 | -1.07 | 0.17 | -0.96 | 0.41 |
| Balance Sheet | |||||||||||
| Total Assets | 820M | 851M | 842M | 919M | 1.06B | 1.34B | 1.28B | 1.40B | 1.32B | 1.10B | 1.12B |
| Total Liabilities | 200M | 228M | 131M | 221M | 357M | 662M | 553M | 444M | 226M | 106M | 111M |
| Shareholders' Equity | 620M | 623M | 711M | 698M | 701M | 674M | 727M | 958M | 1.09B | 989M | 1.01B |
| Cash & Short-term Investments | 437M | 380M | 200M | 206M | 314M | 267M | 232M | 429M | 254M | 132M | 140M |
| Total Debt | - | - | - | - | 293M | 618M | 496M | 418M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 59.6M | 43.9M | 22.1M | 33.3M | 13.4M | -44.3M | 19.7M | 6.51M | 47.6M | 16.6M | 35.8M |
| Capital Expenditure | 92.7M | 166M | 163M | 91.8M | 18.3M | 332M | 20.2M | 18.9M | 30.3M | 37.7M | 2.31M |
| Free Cash Flow | - | -123M | -141M | -58.6M | -4.90M | -376M | -449K | -12.4M | 17.2M | -21.0M | 33.5M |
| Ratios | |||||||||||
| ROE | 11.0% | 4.5% | 3.5% | 3.0% | 1.0% | -9.3% | -6.1% | -6.0% | 1.1% | -7.0% | 2.9% |
| ROA | 8.3% | 3.3% | 3.0% | 2.3% | 0.7% | -4.7% | -3.5% | -4.1% | 0.9% | -6.3% | 2.6% |
| Net Profit Margin | 9.4% | 5.0% | 4.0% | 3.3% | 1.2% | -13.3% | -10.3% | -14.8% | 3.4% | -22.4% | 7.8% |
| Debt to Equity | - | - | - | - | 0.42x | 0.92x | 0.68x | 0.44x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dabomb Protein dividends
- Dividend yield
- 1.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 8, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 12.2M | 0.17 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | TWD 6.03M | 0.19 | - |
| 2020 | TWD 14.7M | 0.44 | 204.1% |
| 2019 | TWD 23.4M | 0.80 | 110.4% |
| 2018 | TWD 12.8M | 0.44 | 51.1% |
| 2017 | TWD 21.9M | 0.85 | 78.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1100:1000 on Aug 23, 2021.
Who owns Dabomb Protein
- Insiders 57.62%
- Institutions 0.00%
- Public & others 42.38%
- Shares outstanding 71.9M
- Free float 33.2M
Dabomb Protein company profile
- Company name
- Dabomb Protein
- Ticker
- 6578.TWO
- ISIN
- TW0006578008
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Fiscal year end
- December
- Address
- No. 52, Industrial 3rd Rd, Tainan City, Taiwan, 709
- Phone
- 886 0 6384 0771
- Website
- dabombprotein.com
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers nutrition and health care for aquatic products and economic animals; and pet health care products. The company also offers contract development and manufacturing organization services, including research and development, process design, and mass production services; product packaging solutions; and product formulation design and customized development services. It serves pet health food brands, pet nutrition product distribution channels, livestock feed enterprises, animal nutrition brands, and aquaculture industries. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023. DaBomb Protein Biotech Corp. was incorporated in 2001 and is based in Tainan City, Taiwan.
Dabomb Protein management
3- Wei Chen ChenGM & Chairperson
- Yahui YaoAccounting Supervisor
- Jing Xing LiuDeputy General Manager of Marketing Department